- Home
- HY vs PRAX Comparison
HY vs PRAX Comparison
Compare HY & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HY
- PRAX
- Stock Information
- Founded
- HY 1991
- PRAX 2015
- Country
- HY United States
- PRAX United States
- Employees
- HY N/A
- PRAX N/A
- Industry
- HY Construction/Ag Equipment/Trucks
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- HY Industrials
- PRAX Health Care
- Exchange
- HY Nasdaq
- PRAX Nasdaq
- Market Cap
- HY 735.1M
- PRAX 599.7M
- IPO Year
- HY N/A
- PRAX 2020
- Fundamental
- Price
- HY $39.56
- PRAX $36.00
- Analyst Decision
- HY Strong Buy
- PRAX Strong Buy
- Analyst Count
- HY 2
- PRAX 9
- Target Price
- HY $80.00
- PRAX $123.33
- AVG Volume (30 Days)
- HY 85.7K
- PRAX 569.3K
- Earning Date
- HY 05-06-2025
- PRAX 05-12-2025
- Dividend Yield
- HY 3.54%
- PRAX N/A
- EPS Growth
- HY 11.05
- PRAX N/A
- EPS
- HY 8.04
- PRAX N/A
- Revenue
- HY $4,308,200,000.00
- PRAX $8,553,000.00
- Revenue This Year
- HY N/A
- PRAX N/A
- Revenue Next Year
- HY $3.75
- PRAX $789.73
- P/E Ratio
- HY $4.91
- PRAX N/A
- Revenue Growth
- HY 4.61
- PRAX 249.53
- 52 Week Low
- HY $34.13
- PRAX $26.70
- 52 Week High
- HY $84.44
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- HY 46.09
- PRAX 48.79
- Support Level
- HY $37.54
- PRAX $28.79
- Resistance Level
- HY $40.00
- PRAX $37.97
- Average True Range (ATR)
- HY 1.84
- PRAX 2.66
- MACD
- HY 0.51
- PRAX 1.50
- Stochastic Oscillator
- HY 92.50
- PRAX 82.52
About HY Hyster-Yale Materials Handling Inc.
Hyster Yale Inc designs, engineers, manufactures, sells and services a comprehensive line of lift trucks, attachments, aftermarket parts and technology solutions marketed globally under the Hyster and Yale brand names. The Company has five segments, which include three in the lift truck business as discussed below, as well as Bolzoni S.p.A. (Bolzoni) and Nuvera Fuel Cells, LLC (Nuvera). Majority of revenue is from Lift Trucks. geographically operates in America, EMEA, JAPIC, maximum revenue from America.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.